Immune Checkpoint Therapies for Melanoma

被引：4
作者：
Buchbinder, Elizabeth I. [1 ]
机构：
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02481 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 01期
关键词：
Immune checkpoint inhibition; Melanoma; Immunotherapy; RESECTED STAGE-III; COMBINED NIVOLUMAB; ADJUVANT THERAPY; ADVERSE EVENTS; OPEN-LABEL; T-CELLS; IPILIMUMAB; CTLA-4; PD-1; INTERFERON-ALPHA-2B;
D O I：
10.1016/j.hoc.2020.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy with immune checkpoint inhibition has dramatically changed the treatment of melanoma. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte–associated protein 4 and programmed cell death protein 1 are approved for the treatment of advanced melanoma alone and in combination. In addition, these agents are approved for use in high-risk resected stage III melanoma in the adjuvant setting. Clinical trials testing the combination of immune checkpoint inhibition with other therapies and novel immunotherapies continue. This article reviews the current literature on approved uses of immune checkpoint inhibition in melanoma and discusses ongoing trials and future directions. © 2020 Elsevier Inc.
引用
收藏
页码：99 / 109
页数：11
相关论文
共 50 条
  • [21] Success of immune checkpoint blockade therapies - mechanisms and implications for hepatology
    Bengsch, Bertram
    Thimme, Robert
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (01): : 74 - 86
  • [22] Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma
    Wu, Minliang
    Wang, Yuchong
    Xu, Yalong
    Zhu, Ji
    Lv, Chuan
    Sun, Mengyan
    Guo, Rui
    Xia, Yu
    Zhang, Wei
    Xue, Chunyu
    [J]. JOURNAL OF CANCER, 2019, 10 (24): : 6114 - 6123
  • [23] Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors
    Howell, Ashley, V
    Gebregziabher, Mulugeta
    Thiers, Bruce H.
    Graboyes, Evan M.
    Paulos, Chrystal M.
    Wrangle, John M.
    Hunt, Kelly J.
    Wallace, Kristin
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (07) : 1003 - 1010
  • [24] Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity
    Justice, Joy
    Kankaria, Roma A.
    Johnson, Douglas B.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, : 1115 - 1125
  • [25] Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
    Zheng, Qingyue
    Li, Jiarui
    Zhang, Hanlin
    Wang, Yuanzhuo
    Zhang, Shu
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care
    Singh, Sima
    Numan, Arshid
    Agrawal, Nikhil
    Tambuwala, Murtaza M.
    Singh, Vijender
    Kesharwani, Prashant
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 83
  • [27] Pneumotoxicity associated with immune checkpoint inhibitor therapies
    Shannon, Vickie R.
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2017, 23 (04) : 305 - 316
  • [28] Acquired Resistance to Immune Checkpoint Blockade Therapies
    Zhao, Xianda
    Wangmo, Dechen
    Robertson, Matthew
    Subramanian, Subbaya
    [J]. CANCERS, 2020, 12 (05)
  • [29] Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
    Shiuan, Eileen
    Beckermann, Kathryn E.
    Ozgun, Alpaslan
    Kelly, Ciara
    McKean, Meredith
    McQuade, Jennifer
    Thompson, Mary Ann
    Puzanov, Igor
    Greer, John P.
    Rapisuwon, Suthee
    Postow, Michael
    Davies, Michael A.
    Eroglu, Zeynep
    Johnson, Douglas
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [30] Targeted Therapies Combined With Immune Checkpoint Therapy
    Prieto, Peter A.
    Reuben, Alexandre
    Cooper, Zachary A.
    Wargo, Jennifer A.
    [J]. CANCER JOURNAL, 2016, 22 (02) : 138 - 146
12345